Latest Waldenström's macroglobulinemia Stories
SUNNYVALE, Calif., Dec. 22, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.
Filing completed less than two months after first European approval for IMBRUVICA® SUNNYVALE, Calif., Dec. 1, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Latest submission seeks approval for additional blood cancer indication RARITAN, N.J., Oct.
Filing completed just three months after receipt of third FDA approval SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
BREDA, the Netherlands, GHENT, Belgium and WHITE PLAINS, New York, June 10, 2014 /PRNewswire/ -- arGEN-X, a clinical stage biopharmaceutical company focused on creating
- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH
Mayo Clinic researchers say the identification of a mutated gene frequently found in Non-Hodgkin’s Lymphoma may open the door to new treatments. Raleigh, NC
- a meat pie that is usually eaten at Christmas in Quebec